Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

13 digital pharma predictions for 2013

Alex Butler offers up his thirteen digital pharma predictions for the year to come. Last year I gave you six predictions for 2012, you can read my review of these predictions for 2012 here. I thought that as in...

Articles

Commonalities in orphan diseases

Caroline Mathie looks at commonalities in orphan diseases and how they can help to improve efficiencies in the drug development and commercialisation process. Orphan diseases are, by definition, rare and very different – having different treating clinicians and often different...

Articles

Spin-out biotechs: bridging the gap between academia and pha...

Dr Rich Ferrie discusses the partnerships between academia and pharma, and shares his thoughts on some of the main issues that can arise. The Big Pharma R&D model is broken, and increasingly, the large monoliths are laying off research staff and looking to...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital